Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;4(1):81-91.
doi: 10.2147/ndt.s1453.

Depression in Parkinson's disease: health risks, etiology, and treatment options

Pasquale G Frisina  1 , Joan C Borod, Nancy S Foldi, Harriet R Tenenbaum
Affiliations

Depression in Parkinson's disease: health risks, etiology, and treatment options

Pasquale G Frisina et al. Neuropsychiatr Dis Treat. 2008 Feb.

Abstract

Depression is found in about 30%-40% of all patients with Parkinson's disease (PD), but only a small percentage (about 20%) receive treatment. As a consequence, many PD patients suffer with reduced health-related quality of life. To address quality of life in depressed PD patients, we reviewed the literature on the health correlates of depression in PD (eg, cognitive function), etiology of depression in PD, and treatment options (ie, antidepressants, electroconvulsive therapy, and psychotherapy). The current review is unique in its focus on psychosocial aspects, as well as neuropathological factors, of depression in PD. Overall, we conclude that neurochemical (eg, serotonin) and psychosocial factors (eg, coping style, self-esteem, and social support) contribute to the affective disturbances found in this neuropsychiatric population. Therefore, we recommend that a multidisciplinary (eg, pharmacotherapeutic, psychoeducational, and/or psychotherapeutic) approach to treatment be taken with depressed PD patients.

Keywords: Parkinson’s disease; depression; health outcomes; treatment options.

PubMed Disclaimer

References

    1. Anderson J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol Scand. 1980;62:210–19. - PubMed
    1. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71. - PubMed
    1. Bel N, Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther. 1996;278:1064–72. - PubMed
    1. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19:787–805. - PubMed
    1. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869–75. - PubMed